NewsResearch
Bispecific Antibodies in Cancer Treatment: Two Targets, More Questions
Bispecific antibodies can bind two targets at once, often bringing immune cells close to cancer cells. Each product needs its own evidence.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
Two targets, one molecule
Bispecific antibodies are drawing attention in blood cancers and in some solid-tumor studies. The idea behind them is easy to state.
NCI defines a bispecific antibody as a type of antibody that can bind to two different antigens at the same time. NCI adds that these are made in the laboratory and are being studied in both the imaging and the treatment of cancer.
Many are built so that one arm grabs a cancer cell and the other grabs an immune cell. NCI describes one such drug as a two-armed molecule that latches onto tumor cells and T cells at once, bringing them close together and helping the T cells recognize and destroy the cancer cells.
That is the mechanism. It is not, by itself, a result.
This page explains federal sources. It is not medical advice and does not suggest a test or treatment.
A worked example in small cell lung cancer
Tarlatamab is useful to look at because NCI has covered it from trial through approval.
In a clinical trial called DeLLphi-301, tarlatamab was tested in people with small cell lung cancer whose disease had progressed after at least two previous treatments. Many had already had three. Tumors shrank in 40% of people at the lower of the two dose levels tested every two weeks, and in about 32% at the higher one.
In more than half of the people whose tumors shrank, the treatment held the cancer back for at least six months, and in many it lasted nine months or longer. The trial was funded by Amgen, which makes the drug. Results were presented at the ESMO meeting and published in the New England Journal of Medicine.
Notice the detail that headlines drop: the higher dose did not do better. More is not automatically more.
The burden that travels with the benefit
At the ESMO meeting, Pilar Garrido noted that patients need to be hospitalized to manage potentially serious side effects when they first receive the drug. That poses real logistical challenges.
This is the part of a bispecific story that belongs beside the response rate. When a treatment pulls immune cells onto tumor cells, the immune reaction that follows can be severe. Reports should describe hospital care, treatment interruptions, serious infections, and immune reactions, not only how many tumors shrank. Our guide to side effects of cancer treatment covers what monitoring generally involves.
Accelerated approval is a conditional answer
FDA approved tarlatamab for extensive-stage small cell lung cancer that has worsened during or after platinum-based chemotherapy. The approval was based on the trial described above.
NCI notes the condition attached: under this accelerated approval, the maker must run additional trials to confirm that the drug provides a clinical benefit. That obligation is the point. An accelerated approval says the early evidence was strong enough to allow use while better evidence is gathered.
Why one product tells you little about another
- Two targets do not automatically beat one target.
- Benefits in one disease, or in one treatment line, do not carry to all cancers.
- The exact pair of targets, the dosing schedule, and the follow-up time differ by product.
- Early trials are often designed mainly to find a safe dose. A high response in a small, selected group may not predict long-term benefit in wider care.
Bispecific antibodies sit at the join between immunotherapy and targeted therapy, which is part of why coverage of them gets muddled.
Questions about a bispecific headline
- Which two targets does this drug bind?
- Is it approved for this cancer, or still experimental?
- How long did the responses last, and how many people were still being followed?
- What immune-related side effects occurred, and did people need to be hospitalized?
- What treatment was this compared against, if any?
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Bispecific antibodies. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.